Eradication of disseminated adenovirus infection in a pediatric hematopoietic stem cell transplantation recipient using the novel antiviral agent CMX001

Journal of Clinical Virology

Volumn 50, Issue 2, 2011, Pages 167-170

  Paolino, Kris ^a   Sande, Jane ^b   Perez, Evelio ^b   Loechelt, Brett ^b   Jantausch, Barbara ^b   Painter, Wendy ^c   Anderson, Margaret ^c   Tippin, Tim ^c   Lanier, E Randall ^c   Fry, Terry ^b   DeBiasi, Roberta L ^b,d  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c Chimerix Inc   (United States)

^d GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Adenovirus; Antiviral therapy; Stem cell transplantation

Indexed keywords

ALEMTUZUMAB; CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; CYCLOSPORIN A; FLUDARABINE; IMMUNOGLOBULIN; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADENOVIRUS INFECTION; APLASTIC ANEMIA; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; CHILD; DIARRHEA; DRUG TOLERABILITY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOCOMPROMISED PATIENT; KIDNEY FUNCTION; LIVER FUNCTION; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT RESPONSE; VIRUS LOAD;

ADENOVIRUS INFECTIONS, HUMAN; ANTIVIRAL AGENTS; CHILD; CYTOSINE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; PHOSPHONIC ACIDS; POLYMERASE CHAIN REACTION;

EID: 78951485140     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2010.10.016     Document Type: Article

References (15)

1. Myers G.D., Krance R.A., Weiss H., Kuehnle I., Demmler G., Heslop H.E., et al. Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath). Bone Marrow Transplant 2005, 36:1001-1008.
2. Vandenbosch K., Ovetchkine P., Champagne M.A., Haddad E., Alexandrov L., Duval M. Varicella-zoster virus disease is more frequent after cord blood than after bone marrow transplantation. Biol Blood Marrow Transplant 2008, 14:867-871.
3. Boeckh M., Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009, 113:5711-5719.
4. Zaia J., Baden L., Boeckh M.J., Chakrabarti S., Einsele H., Ljungman P., et al. Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant 2009, 44:471-482.
5. Painter G.R., Trost L.C., Lampert B.M., Almond M.R., Buller M., Kern E., et al. CMX001. Anti-smallpox agent, anti-cytomegalovirus agent, viral polymerase inhibitor. Drugs Fut 2008, 33:655.
6. Hartline C.B., Gustin K.M., Wan W.B., Ciesla S.L., Beadle J.R., Hostetler K.Y., et al. Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro. JID 2005, 191:396-399.
7. Toth K., Spencer J.F., Dhar D., Sagartz J.E., Buller R.M., Painter G.R., et al. Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model. Proc Natl Acad Sci USA 2008, 105:7293-7297.
8. La Rosa A.M., Champlin R.E., Mirza N., Gajewski J., Giralt S., Rolston K.V., et al. Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis 2001, 32:871-876.
9. Williams K.M., Agwu A.L., Dabb A.A., Higman M.A., Loeb D.M., Valsamakis A., et al. A clinical algorithm identifies high risk pediatric oncology and bone marrow transplant patients likely to benefit from treatment of adenoviral infection. J Pediatr Hematol Oncol 2009, 31:825-831.
10. Neofytos D., Ojha A., Mookerjee B., Wagner J., Filicko J., Ferber A., et al. Treatment of adenovirus disease in stem cell transplant recipients with cidofovir. Biol Blood Marrow Transplant 2007, 13:74-81.
11. Bordigoni P., Carret A.S., Venard V., Witz F., Le Faou A. Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2001, 32:1290-1297.
12. Paczesny S., Salmon A., Clement L., Venard V., Bordigoni P. Prompt versus preemptive intervention with cidofovir for adenovirus diseases after allogeneic stem cell transplantation: impact on survival in a single center experience of 25 patients. J Pediatr Hematol Oncol 2005, 27:457.
13. Kampmann B., Cubitt D., Walls T., Naik P., Depala M., Samarasinghe S., et al. Improved outcome for children with disseminated adenoviral infection following allogeneic stem cell transplantation. Br J Haematol 2005, 130:595-603.
14. Aldern K.A., Ciesla S.L., Winegarden K.L., Hostetler K.Y. Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol Pharmacol 2003, 63:678-681.
15. Tippin T.K., Lampert B.M., Painter G.R., Lanier E.R. Lipid conjugates of cidofovir and tenofovir, CMX001 and CMX157, are not substrates of human organic anion transporters OAT1 and OAT3. The American Association of Pharmaceutical Scientists Annual Meeting 2010.